Competitive Businesses and Fields and Establishing a Unique Position
First written in FY2016. 7 of 8 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 2 of 9 companies on the "Worse" side.
21 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「We will maximize the product value of 5 major new drugs and strengthen earnings power by expanding the pipeline through in-licensing.」
The company continues to pursue a direction of strengthening competitiveness by maximizing product value and expanding its pipeline. - FY2025RestatedAnnual report
「Maximizing Product Value」
The company continues to position the creation of distinctive products and the maximization of product value as part of the value it provides as a pharmaceutical company. - FY2022RestatedAnnual report
「The company will concentrate resources on its priority areas of cardiology, obstetrics and gynecology, psychiatry, and gastroenterology, maintain its position in these areas, and maximize earnings from new drugs.」
The company identifies maintaining its position in priority areas and maximizing earnings from new drugs as issues to be addressed. - FY2021RestatedAnnual report
「The company will further strengthen its areas of expertise and pursue a strategy of becoming “the only one of its kind,” so that each of its businesses and areas is recognized as something that “only Mochida Pharmaceutical can do” and chosen by customers.」
The company continues to pursue a policy of establishing competitive businesses and areas of expertise and becoming “the only one of its kind.” - FY2020RestatedAnnual report
「The company will further strengthen its areas of expertise and pursue a strategy of becoming “the only one of its kind,” so that each of its businesses and areas is recognized as something that “only Mochida Pharmaceutical can do” and chosen by customers.」
The company continues to pursue a policy of establishing competitive businesses and areas of expertise and becoming “the only one of its kind.” - FY2019RestatedAnnual report
「The company will further strengthen its areas of expertise and pursue a strategy of becoming “the only one of its kind,” so that each of its businesses and areas is recognized as something that “only Mochida Pharmaceutical can do” and chosen by customers.」
The company continues to identify “establishing competitive businesses and areas of expertise” as an issue to be addressed. - FY2018RestatedAnnual report
「The company will further strengthen its areas of expertise and pursue a strategy of becoming “the only one of its kind,” so that each of its businesses and areas is recognized as something that “only Mochida Pharmaceutical can do” and chosen by customers.」
The company continues to identify establishing competitive businesses and areas of expertise, and becoming “the only one of its kind,” as issues to be addressed. - FY2016First statedAnnual report
「The company will further strengthen its areas of expertise and pursue a strategy of becoming “the only one of its kind,” so that each of its businesses and areas is recognized as something that “only Mochida Pharmaceutical can do” and chosen by customers.」
This was identified as the first item among the issues to be addressed.